Browsing by Subject "methotrexate"
Now showing items 21-40 of 49
-
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Dosage Regimens
(2008)Background: Because of its long-term effectiveness in clinical practice, methotrexate (MTX) is currently the preferred disease-modifying antirheumatic drug (DMARD) for patients with active rheumatoid arthritis (RA). However, ... -
Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment
(2004)Background: Infliximab at the dose of 5 mg/kg per infusion has been shown effective for the treatment of active spondyloarthropathies. It is not clear if the 5 mg/kg is required in most patients. Objective: To evaluate the ... -
Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever
(2017)Objective. To assess the efficacy and safety of the interleukin-1β (IL-1β) inhibitor canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) identified from the Greek National Registry for ... -
Major vault protein/lung resistance related protein: A novel biomarker for rheumatoid arthritis
(2021)Objective Rheumatoid arthritis (RA) can lead to joint destruction and early institution of effective treatment can preserve joint function. Biomarkers can establish early diagnosis and predict effect of treatment. Vault ... -
-
-
Meta-analysis of BCOR rearranged sarcomas: challenging the therapeutic approach
(2021)Introduction: BCOR rearranged sarcomas comprise a group of malignant mesenchymal tumors that until recently were classified as Ewing sarcomas or as undifferentiated round cell sarcomas. The identification of alterations ... -
A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease
(2017)Objectives Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in SSc compared to standard treatment. ... -
Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients
(2021)Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods -
P38 MAPK signaling in pemphigus: Implications for skin autoimmunity
(2013)p38 mitogen activated protein kinase (p38 MAPK) signaling plays a major role in the modulation of immune-mediated inflammatory responses and therefore has been linked with several autoimmune diseases. The extent of the ... -
Pharmacogenetics and psoriasis: Is targeted treatment a possibility?
(2017)[No abstract available] -
Radiological and radiotherapeutic approaching of pediatric tumors in head and neck area
(2013)The most common pediatric malignancies in head and neck area consisted of lymphoma, leukemia, brain tumors, neuroblastoma, Wilms' tumor, sarcomas and primarily rhabdomyosarcoma. This review reports in brief radiological ... -
Radiotherapy of early breast cancer in scleroderma patients: Our experience with four cases and a short review of the literature
(2012)Purpose: Connective vascular diseases (CVD), including scleroderma, are reported to represent for some researchers a relative contraindication and for others absolute contraindication for radiotherapy. The purpose of our ... -
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
(2022)Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ... -
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
(2022)Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records ... -
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece
(2022)Etanercept is approved for continuous or intermittent use and flexible dosing in plaque psoriasis (PsO). The objectives of this study were to investigate real-world treatment patterns with etanercept in Greek adults with ... -
The risk of lymphoma development in autoimmune diseases: A meta-analysis
(2005)Background: The risk of development of non-Hodgkin lymphoma (NHL) in autoimmune patients has been investigated in several cohort studies. These studies revealed inconclusive results. To shed some light on this controversy, ... -
The second greek–israeli symposium on autoimmunity and rheumatology: Success through synergy
(2019)[No abstract available] -
Serum laminin and collagen IV in inflammatory bowel disease
(2003)Background/Aims: Laminin and collagen IV have been proposed as extracellular matrix serum markers. Because fibrosis is a major complication of inflammatory bowel disease, serum concentrations of laminin and collagen IV ... -
A sharp decrease of Th17, CXCR3+-Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis
(2022)Psoriasis-an immune-mediated skin disease-implicates in its pathophysiology by circulating pro-inflammatory cell populations, cytokines, and their interactions with the epidermis. The direct effect of approved anti-interleukin- ...